Ascend Capital’s Arbutus Biopharma ABUS Stock Holding History

Ascend Capital’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-290,720	Closed	-$1.45M	–	172
2018 Q1	$1.45M	Buy	+290,720	New	+$1.54M	0.06%	171
2015 Q3	–	Sell	-370,400	Closed	-$4.39M	–	122
2015 Q2	$4.39M	Buy	370,400 +350,400	+1,752%	+$5.33M	0.14%	118
2015 Q1	$349K	Buy	+20,000	New	+$410K	0.01%	160

Other funds holding ABUS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Ascend Capital's ABUS Position: Q2 2018 in Review

Ascend Capital sold out of Arbutus Biopharma (ABUS) in Q2 2018, closing a stake of 290,720 shares — an estimated $1.45M sold.

Ascend Capital first reported a position in ABUS in Q1 2015 and held it in 3 quarters. The position peaked at $4.39M in Q2 2015. 71 funds tracked by Wall St. Rank hold ABUS as of Q2 2018.

Ascend Capital reported no remaining Arbutus Biopharma position as of Q2 2018 after selling out during the quarter.
Ascend Capital sold 290,720 Arbutus Biopharma shares in Q2 2018, an estimated $1.45M.
Ascend Capital first reported a position in Arbutus Biopharma in Q1 2015 and held it in 3 quarters.
Ascend Capital's Arbutus Biopharma position peaked at $4.39M in Q2 2015.
71 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2018.

Based on Ascend Capital's 13F filing for Q2 2018, filed 13 Aug 2018.